Your browser doesn't support javascript.
loading
Effects of a Home-Based Pulmonary Rehabilitation Program in Patients with Chronic Obstructive Pulmonary Disease in GOLD B Group: A Pilot Study.
Vilarinho, Rui; Serra, Lúcia; Coxo, Ricardo; Carvalho, João; Esteves, Cátia; Montes, António Mesquita; Caneiras, Cátia.
Afiliação
  • Vilarinho R; Healthcare Department, Nippon Gases Portugal, 2600-242 Lisbon, Portugal.
  • Serra L; Department of Physiotherapy and Center for Rehabilitation Research (CIR), School of Health, Polytechnic Institute of Porto, 4200-072 Porto, Portugal.
  • Coxo R; Healthcare Department, Nippon Gases Portugal, 2600-242 Lisbon, Portugal.
  • Carvalho J; Healthcare Department, Nippon Gases Portugal, 2600-242 Lisbon, Portugal.
  • Esteves C; Healthcare Department, Nippon Gases Portugal, 2600-242 Lisbon, Portugal.
  • Montes AM; Department of Pulmonology, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center, 1649-028 Lisbon, Portugal.
  • Caneiras C; Healthcare Department, Nippon Gases Portugal, 2600-242 Lisbon, Portugal.
Healthcare (Basel) ; 9(5)2021 May 04.
Article em En | MEDLINE | ID: mdl-34064453
ABSTRACT
Patients with chronic obstructive pulmonary disease (COPD) in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) B group can be included in pulmonary rehabilitation (PR) settings outside the hospitals. This study aimed to explore the feasibility of a home-based pulmonary rehabilitation (HBPR) program and assess its impact on patients with COPD in the GOLD B group. A real-world, pre-post intervention study was conducted with 12 weeks of HBPR (presential home visits and phone calls) using the self-management program Living Well with COPD. The 1-min sit-to-stand test (1MSTS), modified Medical Research Council Questionnaire (mMRC), COPD Assessment Test (CAT), Hospital Anxiety and Depression Scale (HADS), and London Chest Activity of Daily Living (LCADL) were used to assess the impact. Pre-post differences and correlations between changes in outcomes were calculated. In 30 patients (71.6 years, FEV1 (%) 52.8), significant improvements (p < 0.05) were observed on 1MSTS (Pre 17.2, Post 21.2), mMRC (Pre 2.0, Post 1.0), CAT (Pre 16.3, Post 9.9), HADS (Pre 14.4, Post 9.6), and LCADL (Pre 21.0, Post 15.8), with no adverse events reported. When significant, correlations between changes in outcomes were moderate or strong (0.48 ≤ ρ ≤ 0.66). HBPR can be feasible and safe, and it shows the potential to significantly improve outcomes of patients with COPD in the GOLD B group.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Healthcare (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Portugal

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Healthcare (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Portugal